Protech BIO Systems Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Protech BIO Systems Private Limited Pharmaceutical Export Portfolio Dataset — 2 Products, $1.5M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Protech BIO Systems Private Limited — Pharmaceutical Exporter Profile (2026) | 2 Products, $1.5M Trade | TransData Nexus

Protech BIO Systems Private Limited

Indian Pharmaceutical Exporter · Advanced Antibiotics Specialist · $1.5M Total Trade · DGFT Verified

Protech BIO Systems Private Limited is an Indian pharmaceutical exporter with a total trade value of $1.5M across 2 products in 2 therapeutic categories. Based on 92 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Imipenem ($950.0K), Ketorolac ($598.5K), .

Protech BIO Systems Private Limited — Export Portfolio & Destination Treemap

Protech BIO Systems Private Limited pharmaceutical export portfolio — 2 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Protech BIO Systems Private Limited? — Company Overview & Market Position

Protech Bio Systems Private Limited, established on November 6, 1998, is a privately held pharmaceutical company headquartered in New Delhi, India. The company is registered under the Corporate Identification Number (CIN) U24239DL1998PTC096960. As of January 1, 2026, Protech Bio Systems has an authorized capital of ₹6.50 crore and a paid-up capital of ₹2.62 crore. The company operates in the manufacturing sector, focusing on the production of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Protech Bio Systems is unlisted and has a workforce of approximately 60 employees.

What Does Protech BIO Systems Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Imipenem$950.0K 2Ketorolac$598.5K

Protech BIO Systems Private Limited Therapeutic Categories — 2 Specializations

Product Portfolio — Top 2 by Export Value

Protech BIO Systems Private Limited exports 2 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Imipenem	Advanced Antibiotics	$950.0K	19	2.8%	5
2	Ketorolac	Analgesics & Antipyretics	$598.5K	73	0.5%	12

Protech BIO Systems Private Limited exports 2 pharmaceutical products across 2 therapeutic categories with a total export value of $1.5M. The top category is Advanced Antibiotics (61.3% of portfolio), followed by Analgesics & Antipyretics (38.7%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Protech BIO Systems Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Protech Bio Systems Private Limited operates manufacturing facilities in New Delhi, India. The company specializes in the production of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Specific details regarding the capacities and certifications of these facilities are not publicly disclosed.

3Key Leadership

The leadership team at Protech Bio Systems Private Limited comprises:

Rana Rajesh Kumar: Director since September 24, 2004.
Renu Singh: Director since October 1, 2021.
Manmohan Kumar: Director since August 23, 2019.

These individuals are responsible for the strategic direction and operational management of the company.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Protech BIO Systems Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Protech Bio Systems Private Limited's export activities, as per TransData Nexus proprietary trade data from 2022 to 2026, include:

Total Export Value: $1.5 million USD.
Total Shipments: 92.
Products Exported: 2 across 2 therapeutic categories.
Top 5 Products:
Imipenem: $950K, Rank #5, 2.8% market share.
Ketorolac: $599K, Rank #12, 0.5% market share.
Top 3 Categories:
Advanced Antibiotics: 61.3%.
Analgesics & Antipyretics: 38.7%.

Protech BIO Systems Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific information regarding Protech Bio Systems Private Limited's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history is not publicly available.

2WHO & EU GMP

Details regarding Protech Bio Systems Private Limited's WHO prequalification, EU Good Manufacturing Practice (GMP) certificates, and European Directorate for the Quality of Medicines & HealthCare (EDQM) status are not publicly disclosed.

3CDSCO & Indian Regulatory

Specific information regarding Protech Bio Systems Private Limited's Central Drugs Standard Control Organisation (CDSCO) manufacturing licenses, state drug controller approvals, and export No Objection Certificates (NOCs) is not publicly available.

4Recent Regulatory Actions

Protech BIO Systems Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Protech Bio Systems Private Limited operates in the pharmaceutical sector, focusing on finished pharmaceutical formulations. While specific competitors in overlapping categories are not identified, the company's export data indicates a focus on Advanced Antibiotics and Analgesics & Antipyretics. The market share for its top products, such as Imipenem (2.8%) and Ketorolac (0.5%), suggests a presence in these therapeutic areas, though detailed market share comparisons and head-to-head analyses are not publicly available.

2Key Differentiators

Protech Bio Systems Private Limited's key differentiators include its focus on specific therapeutic categories—Advanced Antibiotics and Analgesics & Antipyretics—and a concentrated product portfolio. However, the lack of diversification in its product range may limit its ability to mitigate risks associated with market fluctuations in these specific areas.

3Strategic Position

Protech Bio Systems Private Limited's current strategic direction appears to be centered on the production and export of specific pharmaceutical formulations. The company's future outlook would benefit from diversification in its product portfolio and expansion into additional therapeutic areas to enhance resilience and growth potential.

Buyer Due Diligence Brief — Evaluating Protech BIO Systems Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Protech Bio Systems Private Limited's export data indicates a focused approach with a total export value of $1.5 million USD across 92 shipments. The company's portfolio concentration, with top products accounting for 100% of exports, suggests a reliance on a limited product range. While the company has a consistent export track record, the lack of diversification may impact its ability to adapt to changing market demands.

2Certifications to Verify

Importers should verify the following certifications when considering Protech Bio Systems Private Limited as a supplier:

FDA Registration: Confirm the company's FDA facility registration status.
WHO-GMP Certification: Verify the company's compliance with World Health Organization Good Manufacturing Practice standards.
EU GMP Certification: Ensure the company holds valid EU Good Manufacturing Practice certificates.

Frequently Asked Questions — Protech BIO Systems Private Limited

How many pharmaceutical products does Protech BIO Systems Private Limited export from India?

Protech BIO Systems Private Limited exports 2 pharmaceutical products across 2 therapeutic categories. The top exports are Imipenem ($950.0K), Ketorolac ($598.5K). Total export value is $1.5M.

What is Protech BIO Systems Private Limited's total pharmaceutical export value?

Protech BIO Systems Private Limited's total pharmaceutical export value is $1.5M, based on 92 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Protech BIO Systems Private Limited cover?

Protech BIO Systems Private Limited exports across 2 therapeutic categories. The largest are Advanced Antibiotics (61.3%, 1 products), Analgesics & Antipyretics (38.7%, 1 products).

Get Full Protech BIO Systems Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.